CION Ameerpet
HER2-positive breast cancer makes too much of a growth-signalling protein called HER2, which drives the cancer to grow and spread faster. About 15–20% of breast cancers are HER2-positive. It was once one of the harder subtypes to treat, but HER2-targeted therapy — given with chemotherapy — has transformed outcomes so dramatically that many women are now treated with the goal of cure. At CION, a woman-headed, tumour-board-led team confirms your HER2 status from the biopsy report and builds an accurate plan — without rushed decisions or unnecessary tests.
HER2 stands for human epidermal growth factor receptor 2 — a protein on the surface of breast cells that helps control how they grow. In a HER2-positive breast cancer, the cells carry far too many copies of the HER2 gene (called amplification) and make too much of this protein (over-expression). That excess HER2 acts like a stuck accelerator, driving the cancer to grow and divide faster than average. The result is read directly from your breast cancer biopsy and is one of the key markers used to plan breast cancer treatment in Hyderabad.
About 15–20% of all breast cancers are HER2-positive. What makes this subtype important is that HER2 itself can be targeted: HER2-targeted therapy attaches to the HER2 protein and switches off that growth signal. Because of this, a subtype that was once among the most difficult to treat now has markedly better outcomes — which is exactly why getting the HER2 result right, from an accurate diagnosis, matters so much.
"HER2-positive" describes the biology of the cancer (its receptor status), not how advanced it is. A HER2-positive cancer can be early or advanced — the subtype and the stage are two separate things.
Roughly one in six women diagnosed with breast cancer has the HER2-positive subtype — a sizeable group for whom a specific, highly effective class of treatment exists.
HER2 status comes from the same biopsy report used to plan everything else — ER, PR and HER2 testing, plus grade. The HER2 result decides whether HER2-targeted therapy is used.
HER2-positive breast cancer makes up roughly 15–20% of all breast cancers. A generation ago it was one of the worst-outlook subtypes — but since HER2-targeted therapy entered routine care, outcomes have improved so markedly that many women with early HER2-positive disease are now treated with the goal of cure. That is why confirming HER2 status accurately, with IHC and FISH, is one of the most important steps after diagnosis. Source: NCCN Breast Cancer guidance; ASCO/CAP HER2 testing guidelines.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Your HER2 status is not guessed from how the cancer looks — it is measured in the laboratory on tissue taken at your biopsy. Two tests are used. The first, immunohistochemistry (IHC), stains the tumour to see how much HER2 protein is on the cell surface and gives a score of 0, 1+, 2+ or 3+. The second, FISH (fluorescence in-situ hybridisation), actually counts the copies of the HER2 gene and is used when the IHC result is borderline.
Getting this right is essential, because the HER2 result decides whether HER2-targeted therapy is offered at all. These tumour markers are reported on the same pathology document as your ER, PR and grade.
Little or no HER2 protein is seen on the cancer cells. These cancers are treated as HER2-negative, so HER2-targeted therapy is not used and the plan follows the hormone-receptor result instead.
Strong, complete staining on most cancer cells confirms the tumour is HER2-positive. No further test is needed, and HER2-targeted therapy becomes a central part of the plan.
A 2+ score is "borderline" and cannot decide the result on its own. A FISH test is then run to count HER2 gene copies and settle whether the cancer is HER2-positive or HER2-negative.
Because the HER2 result switches an entire class of treatment on or off, accurate testing — and repeat testing on a second sample when needed — is one of the most important steps in your diagnosis.
Because excess HER2 drives growth, HER2-positive cancers tend to be higher-grade and to grow and spread more quickly than hormone-positive cancers. That sounds alarming, but it is only half the picture: this same biology is exactly what HER2-targeted therapy exploits. Knowing how the subtype behaves helps explain why your treatment is given in a particular order and why HER2-targeted therapy is continued for a full year.
HER2-positive tumours often divide more quickly and are diagnosed at a higher grade than hormone-positive cancers. This is why timely, accurate planning matters and why treatment is often started promptly.
The very protein that speeds up growth is also a precise drug target. HER2-targeted therapy locks onto HER2 and shuts down the growth signal — turning the cancer's main strength into a vulnerability.
HER2-positive breast cancer affects women of all ages, including younger Indian women who are diagnosed earlier than the global average. It is found through the same biopsy testing regardless of age.
HER2 amplification is a change that happens within the tumour. Most women who develop it have done nothing wrong — which is why awareness and prompt evaluation of any breast change matter for everyone.
HER2-positive breast cancer does not have unique symptoms of its own — the warning signs are the same as for any breast cancer. But because this subtype can grow quickly, getting any persistent change checked promptly matters even more. Most breast changes are not cancer, yet the ones that are need to be found early through proper diagnosis.
Often firm and painless, sometimes felt as a thickening. A lump that grows or does not come and go with your period needs review — fast-growing cancers can appear between routine screenings.
Swelling of part of the breast, or a new difference between the two breasts that was not there before.
Puckering, redness, or skin that looks like the peel of an orange (peau d'orange) over the breast.
A newly pulled-in (inverted) nipple, or nipple discharge other than breast milk — especially if it is bloody.
Pain in one spot that is not tied to your menstrual cycle and does not settle over a few weeks.
A fast-moving subtype with its own specific treatment class is exactly the situation where a single doctor's opinion is not enough. CION is a woman-headed, tumour-board-led organisation built for these decisions — accurate HER2 confirmation, a treatment sequence chosen by a full panel rather than one person, and honest answers about what HER2-targeted therapy can and cannot do.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Woman-led, tumour-board-reviewed HER2-positive care — HER2-targeted therapy planned with chemotherapy and surgery — across 35+ centres in Telangana & AP. Call 1800-202-8726.
The defining feature of HER2-positive breast cancer is that it can be hit precisely. HER2-targeted therapy uses anti-HER2 antibodies that lock onto the HER2 protein on the cancer cells and switch off the growth signal — while leaving most healthy cells alone. It is almost always given together with chemotherapy (usually a taxane-based combination), because the two work better in partnership than either does alone.
In higher-risk cancers, two anti-HER2 antibodies may be combined — a "dual HER2 blockade" that targets the protein in two ways at once. This class of treatment is the single biggest reason a subtype once considered among the most difficult to treat now has markedly improved outcomes. At CION, the exact combination and sequence are chosen by the tumour board for your stage and hormone-receptor status.
For most HER2-positive cancers beyond the very smallest, the modern approach is neoadjuvant treatment — HER2-targeted therapy plus chemotherapy given before surgery. This shrinks the tumour, can allow breast-conserving surgery instead of mastectomy, and lets the team see how well the cancer responds, which guides what comes after. Surgery and, where needed, radiation follow.
A defining feature of HER2-positive treatment is that the HER2-targeted part usually continues to complete about one year in total, even after chemotherapy has finished. At CION the whole sequence is set by the tumour board for your stage and hormone-receptor status — so you get the right treatment in the right order, without delay.
This is the most encouraging part of the HER2-positive story. A generation ago, HER2-positive breast cancer was among the worst-outlook subtypes — the same biology that made it grow fast also made it harder to control. The arrival of HER2-targeted therapy changed that picture profoundly. By switching off the HER2 growth signal, this class of treatment has improved survival markedly, and many women with early HER2-positive disease are now treated with the goal of cure.
Outcomes still depend on the stage at diagnosis and how the cancer responds, and no treatment can promise a particular result. But it is fair to say that today's HER2-positive breast cancer is not the disease it was twenty years ago. At CION, 1-year survival outcomes for breast cancer run meaningfully ahead of the national average.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
HER2 status is only one of three markers on your report. A HER2-positive cancer can also be hormone-receptor (ER and/or PR) positive — sometimes called "triple-positive". When that is the case, hormone-receptor-positive breast cancer is also treated with endocrine (hormone) therapy, such as tamoxifen or aromatase inhibitors, in addition to HER2-targeted treatment. This is why your full receptor profile, not just the HER2 result, shapes the plan.
After treatment, follow-up focuses on watching for any sign of recurrence and managing your health. HER2-positive cancers have a somewhat higher tendency to spread to the brain, so new persistent neurological symptoms should always be reported promptly.
A HER2-positive diagnosis moves quickly, and the decisions made in the first few weeks matter. You do not have to navigate them alone. CION offers a clear, woman-led pathway from first consultation to treatment, built around your stage and your full receptor profile — with your first consultation free.
A specialist reviews your biopsy and reports in full, explains what "HER2-positive" means for you, and outlines the likely plan — no rushed decisions, no unnecessary tests.
We make sure your HER2 result is reliable — checking IHC and arranging FISH for borderline 2+ cases — and confirm ER/PR and grade, with up to 50% discounts on diagnostics.
3+ oncologists plan your treatment together — typically neoadjuvant HER2-targeted therapy with chemotherapy, then surgery, radiation, and completing about a year of HER2 therapy.
HER2-targeted therapy, chemotherapy, surgery, radiation and endocrine therapy where needed — with heart monitoring, nutrition, psycho-oncology and transparent costs throughout your care.
Hear from patients treated at CION — diagnosis, treatment path, and where they are today.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.HER2 stands for human epidermal growth factor receptor 2 — a protein that helps breast cells grow. In a HER2-positive cancer, the cells carry too many copies of the HER2 gene and make too much of the protein, which acts like a stuck accelerator and makes the cancer grow faster. About 15–20% of all breast cancers are HER2-positive. The important point is that HER2 itself can be targeted: HER2-targeted therapy attaches to the protein and switches the growth signal off. That is why a subtype once considered difficult to treat now has markedly improved outcomes.
Your HER2 status is measured in the laboratory on tissue from your biopsy, not guessed from how the cancer looks. The first test, immunohistochemistry (IHC), scores how much HER2 protein is on the cells as 0, 1+, 2+ or 3+. A score of 0 or 1+ is HER2-negative and a score of 3+ is HER2-positive. A borderline 2+ result is "equivocal" and a second test — FISH, which counts copies of the HER2 gene — is then done to settle it. Getting this right matters because the result decides whether HER2-targeted therapy is offered at all.
Treatment is built around HER2-targeted therapy — anti-HER2 antibodies that lock onto the HER2 protein — given together with chemotherapy, usually a taxane-based combination. For most cancers beyond the smallest, this is given before surgery (the neoadjuvant approach) to shrink the tumour and reveal how it responds. Surgery and, where needed, radiation follow. A defining feature is that the HER2-targeted part usually continues to complete about a year in total, even after chemotherapy ends. In higher-risk cancers two anti-HER2 antibodies may be combined. At CION the exact combination and order are set by the tumour board for your stage.
Early-stage HER2-positive breast cancer can often be treated with the goal of cure, and many women are cured. This is a genuine change: a generation ago HER2-positive was among the worst-outlook subtypes, but HER2-targeted therapy has improved survival markedly. Advanced (metastatic) HER2-positive cancer is generally not curable but is very treatable — HER2-targeted therapy with chemotherapy, and later antibody-drug conjugates, can control it and extend good-quality life, sometimes for a long time. No treatment can promise a particular result, so your outlook depends on stage and response, which is why an accurate, team-based plan matters.
On average, HER2-positive cancers grow and divide faster than hormone-positive cancers and are often diagnosed at a higher grade. We share this honestly. But the same biology that makes the cancer grow fast is exactly what HER2-targeted therapy exploits — the excess HER2 protein is a precise drug target. So while the subtype is more aggressive by nature, it is also one for which a highly effective, specific class of treatment exists. With modern HER2-targeted therapy, the aggressive label no longer means a poor outlook the way it once did, especially when the cancer is found and treated early.
Yes. HER2 status is only one of three markers checked on your report. A cancer can be HER2-positive and also estrogen- and/or progesterone-receptor positive — sometimes called "triple-positive". When that is the case, hormone (endocrine) therapy, such as tamoxifen or aromatase inhibitors, is added to HER2-targeted treatment, usually for several years, to lower the long-term risk of return. This is why your full receptor profile — not just the HER2 result — shapes the plan. At CION we confirm ER, PR and HER2 together so nothing in your treatment is missed.
HER2-targeted therapy is generally better tolerated than chemotherapy because it aims at HER2 specifically. Its main precaution is that anti-HER2 antibodies can occasionally weaken the heart's pumping strength, so heart function is checked before treatment and periodically during it; this effect is usually reversible when found early. The chemotherapy given alongside has its own effects, such as tiredness and lowered blood counts, which the team manages. HER2-positive cancers also have a somewhat higher tendency to spread to the brain, so any new, persistent headaches, vision changes or balance problems should be reported promptly so they can be checked.
Yes. CION offers a free first consultation for all cancer patients, including women newly diagnosed with HER2-positive breast cancer or seeking a second opinion. It is a full 45-minute consultation — a specialist reviews your biopsy and reports, confirms your HER2 status (checking IHC and arranging FISH for borderline 2+ cases), explains what "HER2-positive" means for your treatment, and gives you a clear, tumour-board-backed plan. There are no rushed decisions and no unnecessary tests, and CION offers up to 50% discounts on diagnostics. You can book on 1800-202-8726 or request a callback through the form on this page.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.